Recent developments in buccal and sublingual delivery systems

Expert Opinion on Drug Delivery

Volumn 9, Issue 6, 2012, Pages 615-628

  Şenel, Sevda ^a   Rathbone, Michael J ^b   Cansz, Merve ^a   Pather, Indiran ^c  

^a HACETTEPE UNIVERSITY   (Turkey)

^b INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^c CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

Author keywords

Allergen; Buccal; Buccal iontophoresis; Oral films; Orally dispersing tablets; Sublingual; Vaccine

Indexed keywords

ALPRAZOLAM; ARIPIPRAZOLE; ASENAPINE; BREAKYL; BUPRENORPHINE PLUS NALOXONE; CANNABIDIOL; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; CLOZAPINE; DESLORATADINE; DONEPEZIL; DRONABINOL; FENTANYL; FENTANYL CITRATE; INTERMEZZO; LAMOTRIGINE; LANSOPRAZOLE; LORAMYC; LORATADINE; METOCLOPRAMIDE; MICONAZOLE; MICONAZOLE NITRATE; MIDAZOLAM; MIRTAZAPINE; NABIXIMOLS; OLANZAPINE; ONDANSETRON; PHENTERMINE; PREDNISOLONE SODIUM PHOSPHATE; RISPERIDONE; RIZATRIPTAN; SELEGILINE; UNCLASSIFIED DRUG; VACCINE; VARDENAFIL; ZOLMITRIPTAN; ZOLPIDEM; ZOLPIDEM TARTRATE;

DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG UPTAKE; ELECTROPORATION; HUMAN; IONTOPHORESIS; NONHUMAN; PATENT; PHOTODYNAMIC THERAPY; REVIEW;

ADMINISTRATION, BUCCAL; ADMINISTRATION, SUBLINGUAL; ANIMALS; CHEEK; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; ELECTROPORATION; HUMANS; IONTOPHORESIS; MOUTH MUCOSA; VACCINES;

EID: 84862081912     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.676040     Document Type: Review

References (86)

1. Pather SI, Rathbone MJ, Senel S. Current status and the future of buccal drug delivery systems. Expert Opin Drug Deliv 2008;5(5):531-42 (Pubitemid 351877432)
2. Douroumis D. Orally disintegrating dosage forms and taste-masking technologies; 2010. Expert Opin Drug Deliv 2011;8(5):665-75
3. Ghosh T, Ghosh A, Prasad D. A Review on new generation orodispersible tablets and its future prospective. Int J Pharm Pharm Sci 2011;3(1):1-7
4. Reflection paper: formulations of choice for the paediatric population. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003782.pdf [Cited 31 January 2012]
5. Development of paediatric medicines: Points to consider in pharmaceutical development (Revised draft). Available from: http://www.who.int/medicines/ services/expertcommittees/pharmprep/Rev2-PaediatricMedicinesDevelopment-QAS08- 257Rev1-8102010.pdf [Cited 31 January 2012]
6. Pather SI, Khankari R, Siebert J. Quick-dissolving intraoral tablets. In: Ghosh TK, Pfister WR, editors. Drug Delivery to the Oral Cavity: Molecules to Market. Taylor & Francis Group; Boca Raton: 2005. p. 291-310
7. Ghosh TK, Chatterjee DJ, Pfister WR, et al. Quick dissolving oral dosage forms: scientific and regulatory considerations from a clinical pharmacology and biopharmaceutics perspective. In: Ghosh TK, Pfister WR, editors. Drug Delivery to the Oral Cavity:Molecules to Market. Taylor & Francis Group; Boca Raton: 2005. p. 337-57
8. AdvaTab™ Orally Disintegrating Tablets (ODT). Available from: http://www.aptalispharmaceuticaltechnologies.com/tech-advatab.html [Cited 31 January 2012]
9. Prosolv® ODT. Available from: http://www.jrspharma.de/Pharma/ wEnglisch/produktinfo/productinfo-prosolv-odt.shtml [Cited 31 January 2012]
10. Ludiflash® as excipient for paediatric use. Available from: http://www.pharmaingredients.basf.com/Documents/ENP/Poster/EN/GENPMD316.pdf [Cited31 January 2012]
11. Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release 2009;139(2):94-107
12. In Pharma Technologist website. Available from: http://www.in- pharmatechnologist.com[Cited 8 February 2012]
13. Siddiqui MDN, Garg G, Sharma PK. A short review on "A novel approach in oral fast dissolving drug delivery system and their patents". Adv Biol Res 2011;5(6):291-303
14. Hearnden V, Sankar V, Hull K, et al. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Deliv Rev 2012;64(1):16-28
15. Puratchikody A, Prasanth VV, Mathew ST, et al. Buccal drug delivery: past, present and future - a review. Int JDrug Deliv 2011;3:171-84
16. Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J Control Release 2011;153(2):106-16
17. Pathan SA, Iqbal Z, Sahani JK, et al. Buccoadhesive drug delivery systems - extensive review on recent patents. Recent Pat Drug Deliv Formul 2008;2(2):177-88
18. Senel S. Potential applications of chitosan in oral mucosal delivery. J Drug Deliv Sci Tech 2010;20(1):23-32
19. Morales JO, McConville JT. Manufacture and characterization of mucoadhesive buccal films. Eur JPharm Biopharm 2011;77(2):187-99
20. Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur JPharm Biopharm 2009;71(3):505-18
21. Pather SI, Siebert JM, Hontz J, et al. Enhanced buccal delivery of fentanyl using the oravescent drug delivery system. Drug Deliv Technol 2001;1(1):54-7
22. Cima Labs, Inc., assignee. Sublingual buccal effervescent. US6974590; 2005
23. BEMA® Technology. Available from: http://www.bdsi.com/BEMA- Technology.aspx [Cited 31 January 2012]
24. Reuters website article. Available from: http://www.reuters.com/article/ 2011/04/05/idUS97931+05-Apr-2011+PRN20110405 [Cited 31 January 2012]
25. INSYS Therapeutics Announces FDA Approval of SUBSYS® Fentanyl Sublingual Spray. Available from: http://www.insysrx.com/investors/recent-news/? page-id=270&link=http://insysrx.mwnewsroom.com/press-releases/ insystherapeutics-announces-fda-approval-ofsubsy-pinksheets-neol-0837674?feed= All [Cited 31 January 2012]
26. Abstral Sublingual Tablets. Available from: http://www.medicines.org.uk/ EMC/medicine/21371/SPC/Abstral+Sublingual+Tablets [Cited 31 January 2012]
27. Generex Oral-lyn. Available from: http://www.generex.com/index.php/id/ 270[Cited 31 January 2012]
28. Reuters website article2. Available from:http://www.reuters.com/article/ 2011/05/26/idUS50920+26-May-2011+RNS20110526 [Cited 1 February 2012]
29. Reckitt Benckiser Pharmaceuticals, Inc. Receives FDA Approval for Suboxone® (Buprenorphine and Naloxone) Sublingual Film C-III. Available from: http://www.rb.com/FDA-Approval-for-Suboxone-Sublingual-FilmC-III [Cited 31 January 2012]
30. FDA News Release. Available from: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm281013.htm [Cited 9 February 2012]
31. Intermezzo website. Available from: http://www.intermezzorx.com [Cited9 February 2012]
32. Senel S, Hincal AA. Drug permeation enhancement via buccal route: possibilities and limitations. J Control Release 2001;72(1-3):133-44
33. Nicolazzo JA, Reed BL, Finnin BC. Buccal penetration enhancers - how do they really work? J Control Release 2005;105(1-2):1-15 (Pubitemid 40805471)
34. Hassan N, Ahad A, Ali M, et al. Chemical permeation enhancers for transbuccal drug delivery. Expert Opin Drug Deliv 2010;7(1):97-112
35. Sohi H, Ahuja A, Ahmad FJ, et al. Critical evaluation of permeation enhancers for oral mucosal drug delivery. Drug Dev Ind Pharm 2010;36(3):254-82
36. Moscicka-Studzinska A, Kijenska E, Ciach T. Electroosmotic flow as a result of buccal iontophoresis - buccal mucosa properties. Eur J Pharm Biopharm 2009;72(3):595-9
37. Ciach T, Moscicka-Studzinska A. Buccal iontophoresis: an opportunity for drug delivery and metabolite monitoring. Drug Discov Today 2011;16(7-8):361-6
38. Jacobsen J. Buccal iontophoretic delivery of atenolol center dot HCl employing anew in vitro three-chamber permeation cell. J Control Release 2001;70(1-2):83-95 (Pubitemid 32144795)
39. Giannola LI, De Caro V, Giandalia G, et al. Diffusion of naltrexone across reconstituted human oral epithelium and histomorphological features. Eur JPharm Biopharm 2007;65(2):238-46 (Pubitemid 46038078)
40. Giannola LI, De Caro V, Giandalia G, et al. Release of naltrexone on buccal mucosa: permeation studies, histological aspects and matrix system design. Eur JPharm Biopharm 2007;67(2):425-33 (Pubitemid 47211903)
41. Moscicka AE, Czarnecka K, Ciach T. IntelliDrug implant for medicine delivery in Alzheimer's disease treatment. Macromol Symp 2007;253:134-8 (Pubitemid 47265435)
42. Oh DH, Chun KH, Jeon SO, et al. Enhanced transbuccal salmon calcitonin (sCT) delivery: Effect of chemical enhancers and electrical assistance on in vitro sCT buccal permeation. Eur JPharm Biopharm 2011;79(2):357-63
43. Hu L, Silva SM, Damaj BB, et al. Transdermal and transbuccal drug delivery systems: enhancement using iontophoretic and chemical approaches. Int J Pharm 2011;421(1):53-62
44. Scholz OA, Wolff A, Schumacher A, et al. Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. Drug Discov Today 2008;13(5-6):247-53
45. Kohnle J, Wolff A. Intelligent drug delivery from the oral cavity. Med Device Technol 2007;18(2):44-5
46. Campisi G, Giannola LI, Florena AM, et al. Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs. J Control Release 2010;145(3):214-20
47. Giannola LI, Paderni C, De Caro V, et al. New prospectives in the delivery of galantamine for elderly patients using the intellidrug intraoral device: in vivo animal studies. Curr Pharm Des 2010;16(6):653-9
48. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11(4):S45-53 (Pubitemid 40562303)
49. Arca HC, Gunbeyaz M, Senel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines 2009;8(7):937-53
50. Senel S. Chitosan-based particulate systems for non-invasive vaccine delivery. Adv Polym Sci 2011;243:111-38
51. Reed SG, Bertholet S, Coler RN, et al. New horizons in adjuvants for vaccine development. Trends Immunol 2009;30(1):23-32
52. Perrie Y, Mohammed AR, Kirby DJ, et al. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 2008;364(2):272-80
53. Corradin G, Giudice Gd. Novel adjuvants for vaccines. Curr Med Chem Anti Inflamm AntiAllergy Agents 2005;4(2):185-91 (Pubitemid 40352665)
54. Kweon MN. Sublingual mucosa: a new vaccination route for systemic and mucosal immunity. Cytokine 2011;54(1):1-5
55. Cuburu N, Kweon MN, Song JH, et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007;25(51):8598-610 (Pubitemid 350192038)
56. Song JH, Nguyen HH, Cuburu N, et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 2008;105(5):1644-9 (Pubitemid 351346568)
57. Hervouet C, Luci C, Cuburu N, et al. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 2010;28(34):5582-90
58. Cuburu N, Kweon MN, Hervouet C, et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic tcells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 2009;183(12):7851-9
59. Ralli-Jain P, Tifrea D, Cheng CM, et al. Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization. Vaccine 2010;28(48):7659-66
60. Cho HJ, Kim JY, Lee Y, et al. Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. Vaccine 2010;28(14):2598-606
61. Zhang T, Hashizume T, Kurita-Ochiai T, et al. Sublingual vaccination with outer membrane protein of Porphyromonas gingivalis and Flt3 ligand elicits protective immunity in the oral cavity. Biochem Biophys Res Commun 2009;390(3):937-41
62. Amuguni JH, Lee S, Kerstein KO, et al. Sublingually administered Bacillus subtilis cells expressing tetanus toxin Cfragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine 2011;29(29-30):4778-84
63. Yu M, Vajdy M. A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations. Vaccine 2011;29(13):2429-36
64. Domm W, Brooks L, Chung HL, et al. Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: association with mucoadhesion and efficient penetration of the sublingual barrier. Vaccine 2011;29(40):7080-9
65. Appledorn DM, Aldhamen YA, Godbehere S, et al. Sublingual administration of an adenovirus serotype 5 (ad5)-based vaccine confirms toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against hiv antigens despite preexisting Ad5 immunity. Clin Vaccine Immunol 2011;18(1):150-60
66. Launay O, Grabar S, Bloch F, et al. Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals. Vaccine 2008;26(32):4073-9
67. Cox LS, Linnemann DL, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117(5):1021-35 (Pubitemid 44308083)
68. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. J Allergy Clin Immunol 2010;126(5):969-75
69. Wise SK, Woody J, Koepp S, et al. Quality of life outcomes with sublingual immunotherapy. Am J Otolaryngol 2009;30(5):305-11
70. Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: Results of a US trial. J Allergy Clin Immunol 2011;127(4):974-U225
71. Review of essential medicine priorities in ear, nose and throat conditions in children. Available from: http://www.who.int/selection-medicines/ committees/subcommittee/2/2nd-NewSection-ENT.pdf [Cited 31 January 2012]
72. Passalacqua G, Guerra L, Pasquali M, et al. Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 2004;93(1):3-12
73. Kuo CH, Wang WL, Chu YT, et al. Sublingual immunotherapy in children: an updated review. Pediatr Neonatol 2009;50(2):44-9
74. Calderon MA, del Rio PR, Demoly P. Sublingual allergen immunotherapy in children: An evidence-based overview. Rev Fr Allergol 2012;52(1):20-25
75. Grazax website. Available from: http://www.grazax.com [Cited 31 January 2012]
76. Razafindratsita A, Saint-Lu N, Mascarell L, et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007;120(2):278-85 (Pubitemid 47411528)
77. ViVac website. Available from: http://www.vivac.se [Cited 31 January 2012]
78. Wainwright M. Photodynamic antimicrobial chemotherapy (PACT). J Antimicrob Chemother 1998;42(1):13-28 (Pubitemid 28356358)
79. Donnelly RF, McCarron PA, Tunney MM. Antifungal photodynamic therapy. Microbiol Res 2008;163(1):1-12 (Pubitemid 350251183)
80. Konopka K, Goslinski T. Photodynamic therapy in dentistry. J Dent Res 2007;86(8):694-707
81. Mima EGD, Pavarina AC, Dovigo LN, et al. Susceptibility of Candida albicans to photodynamic therapy in a murine model of oral candidosis. Oral Surg Oral Med O 2010;109(3):392-401
82. Meisel P, Kocher T. Photodynamic therapy for periodontal diseases: state of the art. J Photochem Photobiol B2005;79(2):159-70 (Pubitemid 40614108)
83. Pereira Gonzales F, Maisch T. Photodynamic inactivation for controlling Candida albicans infections. Fungal Biol 2012;116(1):1-10
84. Donnelly RF, McCarron PA, Tunney MM, et al. Potential of photodynamic therapy in treatment of fungal infections of the mouth. Design and characterisation of a mucoadhesive patch containing toluidine blue O. J Photochem Photobiol B2007;86(1):59-69 (Pubitemid 44835462)
85. Cassidy CM, Tunney MM, McCarron PA, et al. Drug delivery strategies for photodynamic antimicrobial chemotherapy: from benchtop to clinical practice. J Photochem Photobiol B2009;95(2):71-80
86. Negri DRM, Riccomi A, Pinto D, et al. Persistence of mucosal and systemic immune responses following sublingual immunization. Vaccine 2010;28(25):4175-80